Cancer cells are addressed through conventional chemotherapy, resulting in tumour resistance and systemic toxicities affecting organ functions. Nanoparticle (NPs) represent a promising approach to improve chemotherapeutic efficacy and reduce adverse effects. This study aims to improve hepato-renal function by dichloroacetate nanoparticles (DCA-PNPs) and doxorubicin (Dox) combinatorial treatment in Ehrlich ascites carcinoma (EAC) model. Dichloroacetate nanoparticles characterizations showed effective drug encapsulation, optimal particles size, morphology, and distribution. Biochemical analysis showed normalized protein content, improved lipid profile, enhanced liver, kidney functions, antioxidant activity, and decreased oxidative-stress with Dox/DCA-PNPs combination treatment, indicating that NPs-based therapy enhanced therapeutic outcomes and minimized systemic toxicity via mitigated Dox side effects and maintained organ's function. This study elucidates that Dox/DCA-PNPs combination therapy provides a more effective strategy for EAC hepatorenal function improvements.
Dichloroacetate nanoparticles and doxorubicin combinatorial treatment augment the hepato-renal function in Ehrlich ascites carcinoma cells
Amira T Khattab,Mai M. El-Keiy,D. Beltagy,Maha M. Salem
Published 2025 in BMC Research Notes
ABSTRACT
PUBLICATION RECORD
- Publication year
2025
- Venue
BMC Research Notes
- Publication date
2025-11-13
- Fields of study
Medicine
- Identifiers
- External record
- Source metadata
Semantic Scholar, PubMed
CITATION MAP
EXTRACTION MAP
CLAIMS
- No claims are published for this paper.
CONCEPTS
- No concepts are published for this paper.
REFERENCES
Showing 1-74 of 74 references · Page 1 of 1
CITED BY
- No citing papers are available for this paper.
Showing 0-0 of 0 citing papers · Page 1 of 1